Add to ORKGThe author overviews recent research on the effect of mifepristone on uterine leiomyomas and breast and ovarian cancers. Mifepristone seems to have an effect on mutated BRCA-1 genes. (non-author abstract
Mifepristone (MFP) is an antiprogestin that has shown some beneficial effects in breast cancer clini...
Mifepristone is an orally-active progesterone receptor antagonist. When a single dose of mifepriston...
© 2016 Dr. Emma NolanWomen who harbour germline mutations in the tumour suppressor gene BRCA1 have a...
Background: To estimate the efficacy of daily administration of 25 mg mifepristone for the treatment...
transcriptional activation RU486 (mifepristone) has proved to be a remarkably active antiprogesteron...
Background: To estimate the efficacy of daily administration of 25 mg mifepristone for the treatment...
The synthetic steroid mifepristone blocks the growth of ovarian cancer cells, yet the mechanism driv...
Objective: To compare the mechanism of action of raloxifene and gosereline induced shrinkage of leio...
Background & Method: The present study was carried out as a prospective longitudinal study among...
Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled tria
Background: Uterine fibroid are the most common benign tumour of the uterus and is seen in 20% of wo...
AIM: To explore the clinical impact and its molecular regulation on uterine leiomyomas in preoperat...
Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most ...
Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most ...
Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most ...
Mifepristone (MFP) is an antiprogestin that has shown some beneficial effects in breast cancer clini...
Mifepristone is an orally-active progesterone receptor antagonist. When a single dose of mifepriston...
© 2016 Dr. Emma NolanWomen who harbour germline mutations in the tumour suppressor gene BRCA1 have a...
Background: To estimate the efficacy of daily administration of 25 mg mifepristone for the treatment...
transcriptional activation RU486 (mifepristone) has proved to be a remarkably active antiprogesteron...
Background: To estimate the efficacy of daily administration of 25 mg mifepristone for the treatment...
The synthetic steroid mifepristone blocks the growth of ovarian cancer cells, yet the mechanism driv...
Objective: To compare the mechanism of action of raloxifene and gosereline induced shrinkage of leio...
Background & Method: The present study was carried out as a prospective longitudinal study among...
Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled tria
Background: Uterine fibroid are the most common benign tumour of the uterus and is seen in 20% of wo...
AIM: To explore the clinical impact and its molecular regulation on uterine leiomyomas in preoperat...
Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most ...
Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most ...
Pancreatic cancer is a leading cause of cancer mortality and is projected to become the second-most ...
Mifepristone (MFP) is an antiprogestin that has shown some beneficial effects in breast cancer clini...
Mifepristone is an orally-active progesterone receptor antagonist. When a single dose of mifepriston...
© 2016 Dr. Emma NolanWomen who harbour germline mutations in the tumour suppressor gene BRCA1 have a...